ALVR - AlloVir Inc Price/Earnings to Growth Ratio

AlloVir, Inc. (ALVR) is currently experiencing a technological pause due to a revision of its core research. Meanwhile, management is demonstrating high transparency and professionalism in seeking new growth avenues. Growth potential remains driven by the VST platform and transplantation therapies. The PEG fundamental indicator visualizes market value relative to earnings, where 0.00 shows the current value of the metric.

AlloVir Inc (ALVR): Price/Earnings to Growth Ratio from 07/04/2022 to 03/29/2025

Metric breakdowns and analytics for AlloVir, Inc. (ALVR)

- share price and consensus valuation forecast:

Price Performance Chart allovir.com|ALVR - Consensus Target

- market capitalization statistics:

Market Value AlloVir Bio|ALVR - Enterprise Value

- issuer book value statistics:

Net Assets per Share AlloVir|ALVR - Company Book Value|Market Value to Book Value allovir.com|ALVR - Cumulative Company Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

ALVR - Company Net Income|Expected Net Profit AlloVir, Inc.|ALVR - Price to Earnings Ratio|Future Price to Earnings allovir.com|ALVR - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio AlloVir Bio|ALVR - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year AlloVir|ALVR - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months allovir.com|ALVR - Earnings growth in current year|Consensus forecast of earnings per share growth for next year AlloVir, Inc.

General company analysis:ALVR AlloVir Inc

The PEG ratio measures the relationship between a stock's market value and its net income growth rate, where a value below one signals a fundamental undervaluation of the asset. Analyzing historical PEG levels allows for a comparison of earnings dynamics with the scientific efficiency of AlloVir, Inc. (ALVR) management in developing therapies for immunodeficient patients, revealing the potential for capitalization growth amid successful clinical trials.

Competitors of AlloVir, Inc.